SCHEMBL13089641

SCHEMBL13089641

CCn1c(Cn2ccnc2-c2nccs2)nc2ccc(-c3ccccn3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR2 P50052 5/20 0.37
ACSS2 Q9NR19 1/20 0.36
METAP2 P50579 1/20 0.36
NPY5R Q15761 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PI4KA P42356 1/20 0.33
PIK3CG P48736 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
LYN P07948 1/20 0.33
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13089643 0.90 AGTR2 (0.40) AGTR2ACSS2LYNMAPTGAA
SCHEMBL13089642 0.87 METAP2 (0.40) ACSS2METAP2NPY5RPIK3CDPIK3CA
SCHEMBL3059573 0.85 LYN (0.41) AGTR2ACSS2MEN1NPC1RAB9A
SCHEMBL3055143 0.83 AGTR2 (0.36) AGTR2LYN
SCHEMBL13089562 0.83 AGTR2 (0.40) AGTR2ACSS2ADORA2AADORA1LYN
SCHEMBL3062900 0.83 CYP11B2 (0.44) AGTR2RAB9ALYNALDH1A1SMN1; SMN2
SCHEMBL3060923 0.82 CYP11B2 (0.35) AGTR2ACSS2MEN1KMT2AALDH1A1
SCHEMBL3055693 0.81 SRC (0.38) AGTR2ACSS2NPC1LYNHTT
SCHEMBL3063000 0.80 LRRK2 (0.42) AGTR2ACSS2LYNHPGDCYP11B1
SCHEMBL3055160 0.80 S1PR1 (0.38) AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2010-10-21 US disclosed
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2010-10-21 US disclosed
US-7642267-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2010-01-05 US disclosed
US-7642267-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2010-01-05 US disclosed
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2008-09-18 US disclosed
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives NEUROGEN CORPORATION 2008-09-18 US disclosed
US-7300945-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2007-11-27 US disclosed
US-7300945-B2 Benzimidazole and pyridylimidazole derivatives NEUROGEN CORPORATION (US) 2007-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267698-A1 Benzimidazole and Pyridylimidazole Derivatives GABBR1, GABBR2, GABRA2 AGTR2 1639/4885ACSS2 2555/4885METAP2 3548/4885
US-20080227793-A1 Benzimidazole and Pyridylimidazole Derivatives GABBR1, GABBR2, GABRA2 AGTR2 1639/4885ACSS2 2555/4885METAP2 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.